Skip to main content
Bohn Stafleu van Loghum
ZOEKEN
MENU 1 2 3 4
Top

Tip

Swipe om te navigeren naar een ander hoofdstuk

Gepubliceerd in:
Ernstige psychiatrische aandoeningen: reflecties op het concept hoofdstuk lezen eerste hoofdstuk lezen

2021 | OriginalPaper | Hoofdstuk

7. Medicamenteuze en andere biologische behandelstrategieën bij mensen met een psychotische kwetsbaarheid

Auteurs : Dr. S. K. Spoelstra, Drs. F. D. van Es, Prof. dr. L. de Haan, Prof. dr. R. Bruggeman, Dr. H. Knegtering

Gepubliceerd in: Ernstige psychiatrische aandoeningen

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

De geïndividualiseerde, multidimensionale en multidisciplinaire behandeling van mensen met psychotische verschijnselen vereist een goede behandel- en zorgcontext. Het succesvol instellen op een antipsychoticum, ter verlaging van de kans op een recidiefpsychose en een heropname, dient plaats te vinden binnen een breed psychosociaal behandelaanbod. Goede samenwerking met naasten is essentieel. Er lijken geringe verschillen in effectiviteit van antipsychotica op positieve symptomen te bestaan. In de klinische praktijk wordt de keuze voor een antipsychoticum vaak vooral gemaakt op basis van bijwerkingen en soms op basis van de beschikbaarheid van langwerkende varianten van een middel. Depotantipsychotica lijken betere langetermijneffecten te hebben dan orale varianten van dezelfde stof. Staken of verminderen van de dosis van een antipsychoticum dient zeer geleidelijk te gebeuren. Clozapine is bij therapieresistente psychosen een belangrijk middel, al dan niet in combinatie met aripiprazol. Er is beperkte evidentie voor elektroconvulsietherapie (ECT) bij therapieresistente psychosen.
vorige hoofdstuk Methodisch werken aan verandering voor mensen met EPA
volgende hoofdstuk Persisterende depressie
Literatuur
Aleman, A., Enriquez-Geppert, S., Knegtering, H., & Dlabac-de Lange, J. J. (2018). Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials. Neuroscience and Biobehavioral Reviews, 89, 111–118. CrossRef
Aleman, A., Lincoln, T. M., Bruggeman, R., Melle, I., Arends, J., Arango, C., et al. (2017). Treatment of negative symptoms: Where do we stand, and where do we go? Schizophrenia Research, 186, 55–62. CrossRef
Ali, S. A., Mathur, N., Malhotra, A. K., & Braga, R. J. (2019). Electroconvulsive therapy and schizophrenia: A systematic review. Molecular Neuropsychiatry, 5, 75–83. CrossRef
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985). Non-invasive magnetic stimulation of human motor cortex. The Lancet, 325, 1106–1107.
Bogers, J. P. A. M., Schulte, P. F. J., Broekman, T. G., Moleman, P., & De Haan, L. (2018). Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. European Neuropsychopharmacology, 28, 1024–1034. CrossRef
Diamond, R. J. (2011). The medication question: Weighing your mental health treatment options. New York: Norton.
Elwyn, G., Frosch, D., Thomson, R., Joseph-Williams, N., Lloyd, A., Kinnersley, P., et al. (2012). Shared decision-making: A model for clinical practice. Journal of General Internal Medicine, 27, 1361–1367.
Endler, N. S. (1988). The origins of electroconvulsive therapy (ECT). Convulsive Therapy, 4, 5–23. PubMed
Helfer, B., Samara, M. T., Huhn, M., Klupp, E., Leucht, C., Zhu, Y., et al. (2016). Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: A systematic review and meta-analysis. The American Journal of Psychiatry, 173, 876–886.
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., et al. (2019). Comparative efficacy and tolerability of 32 antipsychotic for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet, 394, 939–951. CrossRef
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet, 382, 951–962. CrossRef
Lieberman, J. A., Safferman, A. Z., Pollack, S., Szymanski, S., Johns C. Howard, S., et al. (1994). Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. The American Journal of Psychiatry, 151, 1744–1752.
Luchini, F., Medda, P., Mariani, M. G., Mauri, M., Toni, C., & Perugi, G. (2015). Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World Journal of Psychiatry, 5, 182–192. CrossRef
Marder, S. R., Fleischhacker, W. W., Earley, W., Lu, K., Zhong, Y., Németh, G., et al. (2019). Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. European Neuropsychopharmacology, 20(1), 127–136. CrossRef
Marzouk, T., Winkelbeiner, S., Azizi, H., Malhotra, A. K., & Homan, P. (2019). Transcranial magnetic stimulation for positive symptoms in schizophrenia: A systematic review. Neuropsychobiology., 10, 1–13.
Meijel, B., Van der Gaag, M., Kahn, R. S., & Grypdonck, M. H. (2003). Relapse prevention in patients with schizophrenia: The application of an intervention protocol in nursing practice. Archives of Psychiatric Nursing, 17, 165–172. CrossRef
Petrides, G., Malur, C., Braga, R. J., Bailine, S. H., Schooler, N. R., Malhotra, A. K., et al. (2015). Electroconvulsive therapy augmentation in clozapineresistant schizophrenia: A prospective, randomized study. The American Journal of Psychiatry, 172, 52–58.
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry, 7, 64–77. CrossRef
Sanghani, S. N., Petrides, G., & Kellner, C. H. (2018). Electroconvulsive therapy (ECT) in schizophrenia: A review of recent literature. Current Opinion in Psychiatry, 31, 213–222. CrossRef
Singh, S., Kumar, N., Verma, R., & Nehra, A. (2020). The safety and efficacy of adjunctive 20-Hz repetitive transcranial magnetic stimulation for treatment of negative symptoms in patients with schizphrenia: A double-blind, randomized, sham-controlled study. Indian Journal of Psychiatry, 62, 21–29. CrossRef
Smith, R. C., Leucht, S., & Davis, J. M. (2019). Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl), 236, 545–559. CrossRef
Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., et al. (2017). Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectrums, 22, 415–426. CrossRef
Stiekema, A. P. M., Van Dam, M. T., Bruggeman, R., Redmeijer, J. E., Swart, M., Dethmers, M., et al. (2020). Facilitating recovery of daily functioning in people with a severe mental illness who need longer-term intensive psychiatric services: Results from a cluster randomized controlled trial on cognitive adaption training delivered by nurses. Schizophrenia Bulletin. https://​doi.​org/​10.​1093/​schbul/​sbx135.
Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correl, C. U. l., & Tiihonen, J. (2020). 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62.250 patients with schizophrenia (FIN20). World Psychiatry, 19, 61–68.
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., et al. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry, 74, 686–693. CrossRef
Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. American Journal of Psychiatry, 173, 600–606. CrossRef
Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correl, C. U., & Transkanen, A. (2019). Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry, 76, 499–507. CrossRef
Van der Moolen, A. E. G. M., Slooff, C., Bruggeman, R., & Knegtering, H. (2019). Psycho-educatie. In W. Cahn, I. Myin-Germeys, R. Bruggeman, L. De Haan (Red.), Handboek Schizofrenie Spectrumstoornissen. Utrecht: De Tijdstroom.
Van Dijk, F., De Wit, I., Blankers, M., Sommer, I., & De Haan, L. (2018). The personal antipsychotic choice index. Pharmacopsychiatry., 51, 89–99. CrossRef
Van Es, F. (2018). Biologische interventies. In De psychiater komt over de brug. Handreiking voor psychiaters, Projectgroep PvA (EPA redactie). Utrecht: Nederlandse Vereniging voor Psychiatrie.
Veerman, S. R. T., Schulte, P. F. J., & De Haan, L. (2017a). Treatment for negative symptoms in schizophrenia:a comprehensive review. Drugs, 17, 1423–1459. CrossRef
Veerman, S. R., Schulte, P. F., Deijen, J. B., & De Haan, L. (2017b). Adjunctive memantine in clozapine-treated refractory schizophrenia: An open-label 1-year extension study. Psychological Medicine, 47, 363–375. CrossRef
Ventura, J., Subotnik, K. L., Gitlin, M. J., Gretchen Doorly, D., Ered, A., Villa, K. F., et al. (2015). Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophrenia Research, 161, 407–413. CrossRef
Vermeulen, J., Van Rooijen, G., Doedens, P., Numminen, E., Van Tricht, M., & De Haan, L. (2017). Antipsychotic medication and long-term mortality risk in patients with schizophrenia; A systematic review and meta-analysis. Psychological Medicine, 47, 2217–2228. CrossRef
Vermeulen, J. M., Van Rooijen, G., Van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & De Haan, L. (2019). Clozapine and long-term mortality risk in patients with schizophrenia: A systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophrenia Bulletin, 45, 315–329.
Voss, B., Thienel, R., Leucht, S., & Kircher, T. (2008). Therapy of cognitive deficits in schizophrenia with cholineesterase inhibitors, a systematic overview. Nervenarzt., 79, 47–48. CrossRef
Wagner, E., Honer, W. G., Sommer, I. E., Koops, S., Blumberger, D. M., Daskalakis, Z. J., et al. (2020). Repetitive trancranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. World Journal of Biological Psychiatry, 13, 1–13. CrossRef
Wang, G., Zheng, W., Li, X. B., Wang, S. B., Cai, D. B., Yang, X. H., et al. (2018). ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research, 105, 23–32.
Wang, J., Zhou, Y., Gan, H., Pang, J., Li, H., Wang, J., et al. (2017). Efficacy towards negative symptoms and satefy of repetitive transcranial magnetic stimulation treatment for patients with schizophrenia: A systematic review. Shanghai Arch Psychiatry, 29, 61–76. PubMed
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). Recovery in remitted first episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-years randomized clinicial trial. JAMA Psychiatry, 9, 913–920. CrossRef
Zheng, W., Li, X. H., Yang, X. H., Cai, D. B., Ungvari, G. S., Ng, C. H., et al. (2018). Adjunctive memantine for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Psychological Medicine, 48, 72–81. CrossRef
Zhuo, K., Tang, Y., Song, Z., Wang, Y., Wanf, J., Qian, Z., et al. (2019). Repetitive transcaranial magnetic stimulations as adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: A randomized, double-blind, sham controles trial. Neuropsychiatric Disease and Treatment, 8, 1141–1150. CrossRef
Metagegevens
Titel
Medicamenteuze en andere biologische behandelstrategieën bij mensen met een psychotische kwetsbaarheid
Auteurs
Dr. S. K. Spoelstra
Drs. F. D. van Es
Prof. dr. L. de Haan
Prof. dr. R. Bruggeman
Dr. H. Knegtering
Copyright
2021
Uitgeverij
Bohn Stafleu van Loghum
Boek
Ernstige psychiatrische aandoeningen

Print ISBN: 978-90-368-2585-6

Elektronisch ISBN: 978-90-368-2586-3

Copyright: 2021

DOI
https://doi.org/10.1007/978-90-368-2586-3_7